2020; Javle et al. 2014; Ware and Zhu 2020), leading several TGF‐β signalling inhibitors to clinical trials (Liu and Ren 2021; Metropulos et al. 2022; Gulley et al. 2022). Yet, results obtained in cancer clinical studies have been disappointing as none of the pharmacological inhibitors tested so far succeeded in significantly prolonging the survival of cancer patients (Teixeira et al. 2020; Wu et al. 2023). The gene discussed is TGFB1; the disease is cancer.